age-related%20macular%20degeneration
AGE-RELATED MACULAR DEGENERATION
Age-related macular degeneration is a common, chronic, progressive, degenerative disease that causes central loss of vision due to abnormalities that occurs in the pigment, neural and vascular layers of the macula.
The macular disorder may have one or more of the following:
- Formation of drusen which are localized deposits of extracellular material usually concentrated in the macula
- Abnormalities in the retinal pigment epithelium (eg hypopigmentation or hyperpigmentation)
- Retinal pigment epithelium and choriocapillaris geographic atrophy
- Neovascular (exudative) maculopathy
Decreased central vision and distortion of seeing straight lines are the most common symptoms.

Age-related%20macular%20degeneration Management

Follow Up

  • Monocular near vision (using Amsler grid) monitoring should be done in each follow-up exam

Schedule of Follow-up

  • Non-neovascular age-related macular degeneration (AMD)/Intermediate or Advanced AMD in antioxidant vitamin and mineral supplements
    • At 6-24 months after treatment if asymptomatic
    • Advise immediate consultation if new symptoms suggestive of choroidal neovascularization (CNV) occurs
  • Subfoveal neovascular AMD in Ranibizumab therapy
    • Approximately 4 weeks after treatment
    • Subsequent return will be based on the clinical findings
  • Subfoveal neovascular AMD in Pegaptanib sodium therapy
    • Every 6 weeks with retreatments as indicated
  • Subfoveal neovascular AMD after photodynamic therapy (PDT) with Verteporfin
    • Every 3 months until stable, with retreatments as indicated
  • Extrafoveal neovascular AMD after laser photocoagulation therapy
    • At 2-4 weeks after treatment with fundus fluorescein angiography (FFA) and then 4-6 weeks thereafter
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 3 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
06 Sep 2020
Type 2 diabetes mellitus patients taking proton pump inhibitors (PPIs) are at a higher risk of sustaining hip fractures, a recent study has found.
5 days ago
Osteoarthritis (OA) is the most common condition affecting the joints. Dr Lee Eu Jin, an Orthopaedic Surgeon from Liberty Orthopaedic Clinic at Mount Elizabeth Medical Centre, Singapore, shares his insights with Pearl Toh on how to manage OA in the primary care setting.


3 days ago
XOFLUZA – Baloxavir marboxil 20 mg and 40 mg FC tab